We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company delivered an earnings surprise of 6.57%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.(Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $74.82 billion, up 9.4% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $4.08 per share, indicating an improvement of 7.4% from the prior-year quarter’s figure.
Factors to Consider
Cencora is expected to have delivered a moderate performance in the fiscal second quarter, following a strong start in the previous quarter. In its U.S. Healthcare Solutions segment, the company reported 14% revenue growth to $74 billion and a 10% increase in segment operating income. The growth is likely to have continued on the back of strong demand for specialty distribution as well as GLP-1 drugs.
COR’s strong execution in distribution for physician practices and health systems, coupled with growing adoption of biosimilars, positions it well for consistent revenue performance. Moreover, the Retina Consultants of America’s acquisition in January should have brought in additional revenues during the quarter.
However, the declining COVID-19 vaccine contribution might have hurt segmental sales as well as margins. Meanwhile, management expects sluggish growth in GLP-1 drug sales (compared with the 53% year-over-year increase seen in the first quarter).
Our model expects revenues for this segment to be $66.61 billion. Adjusted operating income is estimated to be $901.9 million.
On the international front, Cencora’s Healthcare Solutions segment posted 5.5% revenue growth (8.5% in constant currency) but a 3% decrease in reported operating income in the first quarter. The second quarter is expected to be weaker on a sequential basis, primarily due to a stronger U.S. dollar hurting reported growth, even as constant-currency volumes remain steady.
The company also anticipates a continuation of softer performance in its specialty logistics business, particularly World Courier, due to muted activity in clinical trials and cell and gene therapies. Additionally, macroeconomic and operational softness in certain European and animal health markets may weigh on near-term performance. However, Cencora expects a rebound in the second half of the year as international logistics normalize and currency effects potentially ease.
Our model expects the segment’s adjusted operating income and revenues to be $185.7 million and $7.41 billion, respectively.
Earnings Beat Likely
Our proven model predicts an earnings beat for Cencora this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.82%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Cencora currently has a Zacks Rank #2.
Other Stocks Worth a Look
Here are some other medical stocks worth considering, as these, too, have the right combination of elements to post an earnings beat this reporting cycle.
Premier (PINC - Free Report) has an Earnings ESP of +13.82% and a Zacks Rank #2 at present.
PINC’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 20.43%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a decline of 43.6% from the year-ago reported figure.You can see the complete list of today’s Zacks #1 Rank stocks here.
HealthEquity (HQY - Free Report) has an Earnings ESP of +2.03% and a Zacks Rank #3 at present.
HQY’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 12.78%. The Zacks Consensus Estimate for fiscal first-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Progyny (PGNY - Free Report) has an Earnings ESP of +2.68% and a Zacks Rank #3 at present. The company is scheduled to release first-quarter results on May 8.
PGNY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 54.91%. The Zacks Consensus Estimate for first-quarter EPS implies an improvement of 15.4% from the year-ago reported figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?
Cencora (COR - Free Report) is slated to report second-quarter fiscal 2025 results on May 7, before market open.
In the last reported quarter, the company delivered an earnings surprise of 6.57%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.(Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $74.82 billion, up 9.4% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $4.08 per share, indicating an improvement of 7.4% from the prior-year quarter’s figure.
Factors to Consider
Cencora is expected to have delivered a moderate performance in the fiscal second quarter, following a strong start in the previous quarter. In its U.S. Healthcare Solutions segment, the company reported 14% revenue growth to $74 billion and a 10% increase in segment operating income. The growth is likely to have continued on the back of strong demand for specialty distribution as well as GLP-1 drugs.
COR’s strong execution in distribution for physician practices and health systems, coupled with growing adoption of biosimilars, positions it well for consistent revenue performance. Moreover, the Retina Consultants of America’s acquisition in January should have brought in additional revenues during the quarter.
Cencora, Inc. Price and EPS Surprise
Cencora, Inc. price-eps-surprise | Cencora, Inc. Quote
However, the declining COVID-19 vaccine contribution might have hurt segmental sales as well as margins. Meanwhile, management expects sluggish growth in GLP-1 drug sales (compared with the 53% year-over-year increase seen in the first quarter).
Our model expects revenues for this segment to be $66.61 billion. Adjusted operating income is estimated to be $901.9 million.
On the international front, Cencora’s Healthcare Solutions segment posted 5.5% revenue growth (8.5% in constant currency) but a 3% decrease in reported operating income in the first quarter. The second quarter is expected to be weaker on a sequential basis, primarily due to a stronger U.S. dollar hurting reported growth, even as constant-currency volumes remain steady.
The company also anticipates a continuation of softer performance in its specialty logistics business, particularly World Courier, due to muted activity in clinical trials and cell and gene therapies. Additionally, macroeconomic and operational softness in certain European and animal health markets may weigh on near-term performance. However, Cencora expects a rebound in the second half of the year as international logistics normalize and currency effects potentially ease.
Our model expects the segment’s adjusted operating income and revenues to be $185.7 million and $7.41 billion, respectively.
Earnings Beat Likely
Our proven model predicts an earnings beat for Cencora this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.82%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Cencora currently has a Zacks Rank #2.
Other Stocks Worth a Look
Here are some other medical stocks worth considering, as these, too, have the right combination of elements to post an earnings beat this reporting cycle.
Premier (PINC - Free Report) has an Earnings ESP of +13.82% and a Zacks Rank #2 at present.
PINC’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 20.43%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a decline of 43.6% from the year-ago reported figure.You can see the complete list of today’s Zacks #1 Rank stocks here.
HealthEquity (HQY - Free Report) has an Earnings ESP of +2.03% and a Zacks Rank #3 at present.
HQY’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 12.78%. The Zacks Consensus Estimate for fiscal first-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Progyny (PGNY - Free Report) has an Earnings ESP of +2.68% and a Zacks Rank #3 at present. The company is scheduled to release first-quarter results on May 8.
PGNY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 54.91%. The Zacks Consensus Estimate for first-quarter EPS implies an improvement of 15.4% from the year-ago reported figure.